Euro Pacific Asset Management LLC Takes Position in Sanofi $SNY

Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 43,688 shares of the company’s stock, valued at approximately $2,111,000.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the period. AQR Capital Management LLC raised its position in shares of Sanofi by 107.2% in the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC boosted its position in Sanofi by 19.2% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 42,673 shares of the company’s stock valued at $2,062,000 after purchasing an additional 6,865 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of several analyst reports. Citigroup assumed coverage on Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 23rd. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $61.50.

Sanofi Trading Down 0.1%

Shares of NASDAQ:SNY opened at $46.72 on Tuesday. The business’s 50-day moving average is $46.32 and its 200 day moving average is $47.99. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1 year low of $43.32 and a 1 year high of $55.77. The firm has a market capitalization of $113.95 billion, a P/E ratio of 12.98, a P/E/G ratio of 1.16 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.